Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database-Reference-Cited by-同舟云学术

Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database

Published:2025 Issue: Volume:36 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Motohashi Takashi¹^ORCID,Shimada Muneaki²³^ORCID,Tokunaga Hideki⁴⁵^ORCID,Kuwahara Yuki⁶^ORCID,Kuwabara Hiroyo⁶^ORCID,Kato Ai⁶^ORCID,Tabata Tsutomu¹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Tokyo Women’s Medical University, Tokyo, Japan.

2. Department of Gynecology, Tohoku University Hospital, Sendai, Japan.

3. Department of Clinical Biobank, Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai, Japan.

4. Department of Gynecology, Graduate School of Medicine, Tohoku University, Sendai, Japan.

5. Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

6. Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan.

Funder

Takeda Pharmaceutical Company

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2025.36.e19

Reference31 articles.

1. Clinical statistics of gynecologic cancers in Japan

2. National Cancer Center Japan. Statistical information by cancer type: ovary [Internet]. Tokyo. National Cancer Center Japan. 2022. cited 2023 Aug 22. Available from: https://ganjoho.jp/reg_stat/statistics/stat/cancer/19_ovary.html

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab

4. The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer